Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Functioning gonadotropic adenoma is a very rare pituitary tumor, macroscopically characterized by a soft, well vascularized, variable sized adenoma, with occasional areas of hemorrage or necrosis, that secretes biologically active gonadotropins. In addition to common neurological signs due to mass effect (headache and/or visual field deterioration), additional clinical manifestations include menstrual irregularities (secondary amenorrhea, oligomenorhea or severe menorrhagia), galactorrhea, infertility or ovarian hyperstimulation syndrome (in premenopausal women), testicular enlargement and, occasionally, hypogonadism (in men) and isosexual precocious puberty (in children).
Functioning gonadotropic adenoma is included in newborn screening programs (Malonic Acidemia) in 34 states.
Biomarker and diagnostic research for functioning gonadotropic adenoma has been reported in the published literature.
No clinical trials have been registered for functioning gonadotropic adenoma.
22 publications have been identified in PubMed for functioning gonadotropic adenoma. Research spans Case Report / Case Series (32%), Basic Science / Preclinical (27%), and Clinical Trial Publication (14%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 7 | 32% |
Data assembled from 4 of 12 sources · Last updated Sep 18, 2026, 3:22 AM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Laboratory research
6 |
27% |
Clinical study results | 3 | 14% |
Disease patterns and progression | 3 | 14% |
Testing and diagnosis research | 1 | 5% |
Research summaries | 1 | 5% |
New treatment approaches | 1 | 5% |
Zhang Z (2026). [PMID: 41844162](https://pubmed.ncbi.nlm.nih.gov/41844162/). *Cell Syst*. [Basic Science / Preclinical]
Carretti AL (2026). [PMID: 41060521](https://pubmed.ncbi.nlm.nih.gov/41060521/). *Journal of endocrinological investigation*. [Epidemiology / Natural History]
Zhou J (2026). [PMID: 41501761](https://pubmed.ncbi.nlm.nih.gov/41501761/). *BMC endocrine disorders*. [Case Report / Case Series]
Campana C (2026). [PMID: 41638953](https://pubmed.ncbi.nlm.nih.gov/41638953/). *Best practice & research. Clinical endocrinology & metabolism*. [Review / Meta-Analysis]
Chawla L (2026). [PMID: 41170589](https://pubmed.ncbi.nlm.nih.gov/41170589/). *International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics*. [Diagnostic / Biomarker]
Balderrama D (2026). [PMID: 42037891](https://pubmed.ncbi.nlm.nih.gov/42037891/). *Cureus*. [Case Report / Case Series]
Peeran Z (2025). [PMID: 40667987](https://pubmed.ncbi.nlm.nih.gov/40667987/). *Operative neurosurgery (Hagerstown, Md.)*. [Case Report / Case Series]
Naghiyeva A (2025). [PMID: 40470420](https://pubmed.ncbi.nlm.nih.gov/40470420/). *Cureus*. [Case Report / Case Series]
Liu H (2025). [PMID: 40935899](https://pubmed.ncbi.nlm.nih.gov/40935899/). *British journal of cancer*. [Case Report / Case Series]
Rak-Makowska B (2025). [PMID: 41051622](https://pubmed.ncbi.nlm.nih.gov/41051622/). *Endocrine*. [Epidemiology / Natural History]